Table of Content

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study
2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key findings

3.2.1.    Top investment pockets
3.2.2.    Top winning strategies, 2016–2018
3.2.3.    Top strategies:

3.3.    Porters five forces analysis

3.3.1.    Bargaining power of suppliers
3.3.2.    Threat of new entrants
3.3.3.    Threat of substitutes
3.3.4.    Competitive rivalry
3.3.5.    Bargaining power among buyers

3.4.    Market share analysis, 2018
3.5.    Market dynamics

3.5.1.    Drivers

3.5.1.1.    Surge in prevalence of pneumonia across the globe
3.5.1.2.    Rise in government focus on immunization programs for pneumonia
3.5.1.3.    Increase in focus for novel pneumococcal vaccines

3.5.2.    Restraints

3.5.2.1.    Longer timelines required for pneumonia vaccine production
3.5.2.2.    High cost associated with development of such vaccines

3.5.3.    Opportunity

3.5.3.1.    Development of protein-based combination pneumococcal vaccines

CHAPTER 4:    PNEUMONIA VACCINES MARKET, BY VACCINE TYPE

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Pneumococcal conjugate vaccine (PCV)

4.2.1.    Key market trends, growth factors and opportunities
4.2.2.    Market size and forecast

4.3.    Pneumococcal polysaccharide vaccine (PPSV/PPV)

4.3.1.    Key market trends, growth factors and opportunities
4.3.2.    Market size and forecast

CHAPTER 5:    PNEUMONIA VACCINES MARKET, BY PRODUCT TYPE

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Prevnar 13

5.2.1.    Key market trends, growth factors and opportunities
5.2.2.    Market size and forecast

5.3.    Synflorix

5.3.1.    Key market trends, growth factors and opportunities
5.3.2.    Market size and forecast

5.4.    Pneumovax23

5.4.1.    Key market trends, growth factors and opportunities
5.4.2.    Market size and forecast

5.5.    Pipeline Products

CHAPTER 6:    PNEUMONIA VACCINES MARKET, BY SECTOR

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Public sector

6.2.1.    Market size and forecast

6.3.    Private sector

6.3.1.    Market size and forecast

CHAPTER 7:    PNEUMONIA VACCINES MARKET, BY DISTRIBUTION CHANNEL

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    Distribution partner companies

7.2.1.    Key market trends, growth factors and opportunities
7.2.2.    Market size and forecast

7.3.    Non-governmental Organizations (NGO)

7.3.1.    Key market trends, growth factors and opportunities
7.3.2.    Market size and forecast

7.4.    Government Authorities

7.4.1.    Key market trends, growth factors and opportunities
7.4.2.    Market size and forecast

CHAPTER 8:    GLOBAL PNEUMONIA MARKET, BY REGION

8.1.    Overview

8.1.1.    Market size and forecast

8.2.    North America

8.2.1.    Key market trends
8.2.2.    Key growth factors and opportunities
8.2.3.    Market size and forecast, by type
8.2.4.    Market size and forecast, by product type
8.2.5.    Market size and forecast, by distribution channel
8.2.6.    Market size and forecast, by sector
8.2.7.    Market size and forecast, by country

8.2.7.1.    The U.S. Pneumonia Vaccine Market

8.2.7.1.1.    Market Size and forecast, by type
8.2.7.1.2.    Market Size and forecast, by product type
8.2.7.1.3.    Market Size and forecast, by distribution channel
8.2.7.1.4.    Market Size and forecast, by sector

8.2.7.2.    Canada Pneumonia Vaccine Market

8.2.7.2.1.    Market Size and forecast, by type
8.2.7.2.2.    Market Size and forecast, by product type
8.2.7.2.3.    Market Size and forecast, by distribution channel
8.2.7.2.4.    Market Size and forecast, by sector

8.2.7.3.    Mexico Pneumonia Vaccine Market

8.2.7.3.1.    Market Size and forecast, by type
8.2.7.3.2.    Market Size and forecast, by product type
8.2.7.3.3.    Market Size and forecast, by distribution channel
8.2.7.3.4.    Market Size and forecast, by sector

8.3.    Europe

8.3.1.    Key market trends
8.3.2.    Key growth factors and opportunities
8.3.3.    Market size and forecast, by type
8.3.4.    Market size and forecast, by product type
8.3.5.    Market size and forecast, by distribution channel
8.3.6.    Market size and forecast, by sector
8.3.7.    Market size and forecast, by country

8.3.7.1.    Germany Pneumonia Vaccine Market

8.3.7.1.1.    Market Size and forecast, by type
8.3.7.1.2.    Market Size and forecast, by product type
8.3.7.1.3.    Market Size and forecast, by distribution channel
8.3.7.1.4.    Market Size and forecast, by sector

8.3.7.2.    France Pneumonia Vaccine Market

8.3.7.2.1.    Market Size and forecast, by type
8.3.7.2.2.    Market Size and forecast, by product type
8.3.7.2.3.    Market Size and forecast, by distribution channel
8.3.7.2.4.    Market Size and forecast, by sector

8.3.7.3.    UK Pneumonia Vaccine Market

8.3.7.3.1.    Market Size and forecast, by type
8.3.7.3.2.    Market Size and forecast, by product type
8.3.7.3.3.    Market Size and forecast, by distribution channel
8.3.7.3.4.    Market Size and forecast, by sector

8.3.7.4.    Spain Pneumonia Vaccine Market

8.3.7.4.1.    Market Size and forecast, by type
8.3.7.4.2.    Market Size and forecast, by product type
8.3.7.4.3.    Market Size and forecast, by distribution channel
8.3.7.4.4.    Market Size and forecast, by sector

8.3.7.5.    Italy Pneumonia Vaccine Market

8.3.7.5.1.    Market Size and forecast, by type
8.3.7.5.2.    Market Size and forecast, by product type
8.3.7.5.3.    Market Size and forecast, by distribution channel
8.3.7.5.4.    Market Size and forecast, by sector

8.3.7.6.    Rest of Europe Pneumonia Vaccine Market

8.3.7.6.1.    Market Size and forecast, by type
8.3.7.6.2.    Market Size and forecast, by product type
8.3.7.6.3.    Market Size and forecast, by distribution channel
8.3.7.6.4.    Market Size and forecast, by sector

8.4.    Asia-Pacific

8.4.1.    Key market trends
8.4.2.    Key growth factors and opportunities
8.4.3.    Market size and forecast, by type
8.4.4.    Market size and forecast, by product type
8.4.5.    Market size and forecast, by distribution channel
8.4.6.    Market size and forecast, by sector
8.4.7.    Market size and forecast, by country

8.4.7.1.    Japan Pneumonia Vaccine Market

8.4.7.1.1.    Market Size and forecast, by type
8.4.7.1.2.    Market Size and forecast, by product type
8.4.7.1.3.    Market Size and forecast, by distribution channel
8.4.7.1.4.    Market Size and forecast, by sector

8.4.7.2.    China Pneumonia Vaccine Market

8.4.7.2.1.    Market Size and forecast, by type
8.4.7.2.2.    Market Size and forecast, by product type
8.4.7.2.3.    Market Size and forecast, by distribution channel
8.4.7.2.4.    Market Size and forecast, by sector

8.4.7.3.    India Pneumonia Vaccine Market

8.4.7.3.1.    Market Size and forecast, by type
8.4.7.3.2.    Market Size and forecast, by product type
8.4.7.3.3.    Market Size and forecast, by distribution channel
8.4.7.3.4.    Market Size and forecast, by sector

8.4.7.4.    Rest of Asia-Pacific Pneumonia Vaccine Market

8.4.7.4.1.    Market Size and forecast, by type
8.4.7.4.2.    Market Size and forecast, by product type
8.4.7.4.3.    Market Size and forecast, by distribution channel
8.4.7.4.4.    Market Size and forecast, by sector

8.5.    LAMEA

8.5.1.    Key market trends
8.5.2.    Key growth factors and opportunities
8.5.3.    Market size and forecast, by type
8.5.4.    Market size and forecast, by product type
8.5.5.    Market size and forecast, by distribution channel
8.5.6.    Market size and forecast, by sector
8.5.7.    Market size and forecast, by country

8.5.7.1.    Brazil Pneumonia Vaccine Market

8.5.7.1.1.    Market Size and forecast, by type
8.5.7.1.2.    Market Size and forecast, by product type
8.5.7.1.3.    Market Size and forecast, by distribution channel
8.5.7.1.4.    Market Size and forecast, by sector

8.5.7.2.    South Africa Pneumonia Vaccine Market

8.5.7.2.1.    Market Size and forecast, by type
8.5.7.2.2.    Market Size and forecast, by product type
8.5.7.2.3.    Market Size and forecast, by distribution channel
8.5.7.2.4.    Market Size and forecast, by sector

8.5.7.3.    Saudi Arabia Pneumonia Vaccine Market

8.5.7.3.1.    Market Size and forecast, by type
8.5.7.3.2.    Market Size and forecast, by product type
8.5.7.3.3.    Market Size and forecast, by distribution channel
8.5.7.3.4.    Market Size and forecast, by sector

8.5.7.4.    Rest of LAMEA Pneumonia Vaccine Market

8.5.7.4.1.    Market Size and forecast, by type
8.5.7.4.2.    Market Size and forecast, by product type
8.5.7.4.3.    Market Size and forecast, by distribution channel
8.5.7.4.4.    Market Size and forecast, by sector

CHAPTER 9:    COMPANY PROFILES

9.1.    GLAXOSMITHKLINE PLC.

9.1.1.    Company overview
9.1.2.    Company snapshot
9.1.3.    Operating business segments
9.1.4.    Product Portfolio
9.1.5.    Business performance

9.2.    LG CHEM LTD.

9.2.1.    Company overview
9.2.2.    Company snapshot
9.2.3.    Operating business segments
9.2.4.    Product portfolio
9.2.5.    Business performance

9.3.    MERCK & CO., INC.

9.3.1.    Company overview
9.3.2.    Company snapshot
9.3.3.    Operating business segments
9.3.4.    Product Portfolio
9.3.5.    Business performance

9.4.    PANACEA BIOTEC LIMITED

9.4.1.    Company overview
9.4.2.    Company snapshot
9.4.3.    Operating business segments
9.4.4.    Product portfolio
9.4.5.    Business performance

9.5.    PFIZER INC.

9.5.1.    Company overview
9.5.2.    Company snapshot
9.5.3.    Operating business segments
9.5.4.    Product portfolio
9.5.5.    Business performance

9.6.    PNUVAX INCORPORATED

9.6.1.    Company overview
9.6.2.    Company snapshot
9.6.3.    Product portfolio

9.7.    SERUM INSTITUTE OF INDIA PVT. LTD.

9.7.1.    Company overview
9.7.2.    Company snapshot
9.7.3.    Product portfolio

9.8.    SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)

9.8.1.    Company overview
9.8.2.    Company snapshot
9.8.3.    Product portfolio

9.9.    SK BIOSCIENCE

9.9.1.    Company overview
9.9.2.    Company snapshot
9.9.3.    Product portfolio

9.10.    WALVAX BIOTECHNOLOGY CO., LTD.

9.10.1.    Company overview
9.10.2.    Company snapshot
9.10.3.    Product Portfolio

LIST OF TABLES

TABLE 01.    PNEUMONIA VACCINES MARKET, BY VACCINE TYPE, 2017–2025 ($MILLION)
TABLE 02.    PNEUMONIA VACCINES MARKET FOR PNEUMOCOCCAL CONJUGATE VACCINES, BY REGION, 2017–2025 ($MILLION)
TABLE 03.    PNEUMONIA VACCINES MARKET FOR PNEUMOCOCCAL POLYSACCHARIDE VACCINES, BY REGION, 2017–2025 ($MILLION)
TABLE 04.    PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 05.    PNEUMONIA VACCINE MARKET FOR PREVNAR 13, BY REGION, 2017–2025 ($MILLION)
TABLE 06.    PNEUMONIA VACCINE MARKET FOR PREVNAR 13, BY TARGET POPULATION, 2017–2025 ($MILLION)
TABLE 07.    PNEUMONIA VACCINE MARKET FOR SYNFLORIX, BY REGION, 2017–2025 ($MILLION)
TABLE 08.    PNEUMONIA VACCINE MARKET FOR SYNFLORIX, BY TARGET POPULATION, 2017–2025 ($MILLION)
TABLE 09.    PNEUMONIA VACCINE MARKET FOR PNEUMOVAX23, BY REGION, 2017–2025 ($MILLION)
TABLE 10.    PNEUMONIA VACCINE MARKET FOR PNEUMOVAX, BY TARGET POPULATION, 2017–2025 ($MILLION)
TABLE 11.    PNEUMONIA VACCINE PRODUCT PIPELINE
TABLE 12.    PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 13.    PNEUMONIA VACCINE MARKET BY PUBLIC SECTOR, 2017–2025 ($MILLION)
TABLE 14.    PNEUMONIA VACCINE MARKET, BY PRIVATE SECTOR, 2017–2025 ($MILLION)
TABLE 15.    PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 16.    PNEUMONIA VACCINE MARKET FOR DISTRIBUTION PARTNER COMPANIES, BY REGION, 2017–2025 ($MILLION)
TABLE 17.    PNEUMONIA VACCINE MARKET FOR NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2017–2025 ($MILLION)
TABLE 18.    PNEUMONIA VACCINE MARKET FOR GOVERNMENT AUTHORITIES, BY REGION, 2017–2025 ($MILLION)
TABLE 19.    PNEUMONIA VACCINE MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 20.    NORTH AMERICA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 21.    NORTH AMERICA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 22.    NORTH AMERICAPNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 23.    NORTH AMERICAPNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 24.    NORTH AMERICA PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 25.    THE U.S. PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 26.    THE U.S. PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 27.    THE U.S. PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 28.    THE U.S. PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 29.    CANADA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 30.    CANADA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 31.    CANADA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 32.    CANADA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 33.    MEXICO PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 34.    MEXICO PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 35.    MEXICO PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 36.    MEXICO PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 37.    EUROPE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 38.    EUROPE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 39.    EUROPE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 40.    EUROPE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 41.    EUROPE PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 42.    GERMANY PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 43.    GERMANY PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 44.    GERMANY PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 45.    GERMANY PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 46.    FRANCE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 47.    FRANCE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 48.    FRANCE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 49.    FRANCE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 50.    UK PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 51.    UK PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 52.    UK PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 53.    UK PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 54.    SPAIN PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 55.    SPAIN PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 56.    SPAIN PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 57.    SPAIN PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 58.    ITALY PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 59.    ITALY PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 60.    ITALY PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 61.    ITALY PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 62.    REST OF EUROPE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 63.    REST OF EUROPE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 64.    REST OF EUROPE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 65.    REST OF EUROPE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 66.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 67.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 68.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 69.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 70.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 71.    JAPAN PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 72.    JAPAN PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 73.    JAPAN PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 74.    JAPAN PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 75.    CHINA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 76.    CHINA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 77.    CHINA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 78.    CHINA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 79.    INDIA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 80.    INDIA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 81.    INDIA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 82.    INDIA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 83.    REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 84.    REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 85.    REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 86.    REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 87.    LAMEA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 88.    LAMEA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 89.    LAMEA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 90.    LAMEA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 91.    LAMEA PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 92.    BRAZIL PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 93.    BRAZIL PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 94.    BRAZIL PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 95.    BRAZIL PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 96.    SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 97.    SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 98.    SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 99.    SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 100.    SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 101.    SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 102.    SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 103.    SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 104.    REST OF LAMEA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 105.    REST OF LAMEA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 106.    REST OF LAMEA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 107.    REST OF LAMEA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 108.    GSK: COMPANY SNAPSHOT
TABLE 109.    GSK: OPERATING SEGMENTS
TABLE 110.    GSK: PRODUCT PORTFOLIO
TABLE 111.    LG CHEM: COMPANY SNAPSHOT
TABLE 112.    LG CHEM: OPERATING SEGMENTS
TABLE 113.    KINDER MORGAN: PRODUCT PORTFOLIO
TABLE 114.    MERCK: COMPANY SNAPSHOT
TABLE 115.    MERCK: OPERATING SEGMENTS
TABLE 116.    MERCK: PRODUCT PORTFOLIO
TABLE 117.    PANACEA BIOTEC: COMPANY SNAPSHOT
TABLE 118.    PANACEA BIOTEC: OPERATING SEGMENTS
TABLE 119.    PANACEA BIOTEC: PRODUCT PORTFOLIO
TABLE 120.    PFIZER: COMPANY SNAPSHOT
TABLE 121.    PFIZER: OPERATING SEGMENTS
TABLE 122.    PFIZER: PRODUCT PORTFOLIO
TABLE 123.    PNUVAX: COMPANY SNAPSHOT
TABLE 124.    PNUVAX: PRODUCT PORTFOLIO
TABLE 125.    SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 126.    SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 127.    SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.: COMPANY SNAPSHOT
TABLE 128.    SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.: PRODUCT PORTFOLIO
TABLE 129.    SK BIOSCIENCE: COMPANY SNAPSHOT
TABLE 130.    SK BIOSCIENCE: PRODUCT PORTFOLIO
TABLE 131.    WALVAX: COMPANY SNAPSHOT
TABLE 132.    WALVAX: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    PNEUMONIA VACCINES MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    BARGAINING POWER OF SUPPLIERS
FIGURE 04.    THREAT OF NEW ENTRANTS
FIGURE 05.    THREAT OF SUBSTITUTES
FIGURE 06.    COMPETITIVE RIVALRY
FIGURE 07.    BARGAINING POWER AMONG BUYERS
FIGURE 08.    MARKET SHARE ANALYSIS, 2018
FIGURE 09.    IMPACT ANALYSIS
FIGURE 10.    GSK: REVENUE, 2016–2018 ($MILLION)
FIGURE 11.    GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 12.    GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 13.    LG CHEM: NET SALES, 2015–2017 ($MILLION)
FIGURE 14.    LG CHEM: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 15.    LG CHEM: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 16.    MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 17.    MERCK: NET SALES BY SEGMENT, 2018 (%)
FIGURE 18.    MERCK: NET SALES BY REGION, 2018 (%)
FIGURE 19.    PANACEA BIOTEC: NET SALES, 2016–2018 ($MILLION)
FIGURE 20.    PANACEA BIOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 21.    PANACEA BIOTEC: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 22.    PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 23.    PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24.    PFIZER: REVENUE SHARE BY REGION, 2018 (%)